Thursday, September 27, 2001
Introduction and Review of Basic Pharmacokinetics, related responses, and Clinical Applications

8:30 AM - Registration
9:00 AM - Welcome - Dra. Azucena Aldaz
9:15 AM - Introduction to basic concepts in pharmacokinetics, including
        Review of Basic Pharmacokinetic behavior.
        Elimination and Renal Function Dr. Jelliffe
9:30 AM - Evaluating Renal Function Dr. Jelliffe
9:45 AM –Bayes’ Theorem and the MAP Bayesian Scenario of Planning, monitoring, and Adjusting  drug dosage for patients - Dr. Jelliffe 
10:00 AM - Introduction to the USC*PACK MAP Bayesian Clinical Program - Using PK software to Optimize drug dosage. 
           Demo - 1 compartment model: Planning the Initial regimen Gentamicin: CCr = 100, 25.
10:15 AM - Modeling diffusion into endocardial vegetations, and the postantibiotic effect. 
10:30 AM - Modeling bacterial growth and kill
        An interesting patient on an aminoglycoside.
10:45 AM – Optimizing Transplant Chemotherapy and Improving Patient Care -
	Dr. Bleyzac

11:15 AM BREAK

11:30 AM - Hands on session - Dr. Jelliffe
        Gentamicin: Setting the initial goals, planning the initial regimen
        Entering past doses and levels, analyzing the data. 
        Modeling diffusion into endocardial vegetations, and the postantibiotic effect. 
        Modeling bacterial growth and kill
        The interesting case of aminoglycoside therapy.

12:30 PM LUNCH
1:30 PM - Demo 2 compartment model Digoxin - Dr. Jelliffe
        Setting the initial goals, planning the initial regimen
        A simple patient with atrial fibrillation
        Another interesting patient with atrial fib 
2:00 PM - Hands on session - Setting the initial goals, planning the initial regimen. 
        The simpler patient with atrial fib

3:00 PM BREAK


3:15 PM – The behavior of Cyclosporine – Speaker from Valencia
3:45 PM - Demo Vancomycin - Setting the initial goals, planning the initial regimen. - Dr. Jelliffe 
4:00 PM - Hands on session - Setting the initial goals, planning the initial regimen.
4:30 PM – The behavior of Iforfamide - Speaker from Valencia

Friday, September 28, 2001

8:30 AM – Optimizing Cancer Chemotherapy – Dr. Murry
9:30 AM - Introduction to Population Modelling - Dr. Jelliffe
        Why model? For description? For action? For what purpose?
        Types of PK models
        Linear regression, NLLS
9:45 AM - Parametric Population Models
        Iterative 2 stage Bayesian, NONMEM
10:00 AM - Nonparametric Population models: NPEM, NPML
10:15 AM - Optimal procedures for population modelling 
        First, determine the assay error pattern polynomial, to weight each data point properly 
        Second, use a parametric population model, get gamma, ranges 
        Third, use an NP population model, use gamma, ranges, get the entire parameter 
        distribution. Why?

10:30 AM BREAK

10:45 AM - A new NPEM (NPAG) with an Adaptive Grid – Dr. Jelliffe
11:15 AM - Multiple Model Dosage Design for maximum precision regimens – Dr. Jelliffe
11:30 AM - Demo getting the assay error polynomial - Dr. Jelliffe

12:00 Noon LUNCH

1:00 PM - Demo The IT2B program. Modelling Amikacin - Dr. Jelliffe
        A typical patient data file
        Running the program. Getting gamma, ranges, evaluating the results
1:30 PM - Hands-on session Modelling Amikacin
        Running the program. Getting gamma, ranges, evaluating the results

2:30 PM BREAK

2:45 PM - Demo NPAG: Modelling Amikacin further. Using gamma, ranges 
        Evaluating the results - Dr. Jelliffe 
        The log-likelihood function
        Descriptors of dispersion : The DF50 and DF95
        The 2 and 3-D plots of the marginal and joint marginal PDF’s
3:15 PM - Hands-on session - NPAG: Modelling Amikacin further. Using gamma, ranges - Dr. Jelliffe 
        Linking Nonparametric Models to Multiple Model Adaptive Control 
        Deriving individual Bayesian posterior patient parameter joint densities 
        Evaluating relationships between parameters and covariates
4:30 PM – Comparing Parametric and Nonparametric Population Models – Ms. Bustad

Saturday, September 29, 2001

8:30 AM – Minimizing the Emergence of Bacterial Resistance– Dr. Drusano

Advanced population PK/PD Modelling

9:15 AM – Computer Clusters and Web Access for Making Large PK/PD Models – Dr. Jelliffe
9:45 AM - Making large and nonlinear population models – Dr. Hoem
        Demo - Using BOXES making a Michaelis-Menten model of Cyclosporine
10:00 AM - Hands on session - Using BOXES making a Michaelis-Menten model of Cyclosporine - Dr. Hoem

10:30 AM BREAK

10:45 AM - Demo setting up Big IT2B Modelling Cyclosporine - Dr. Hoem
        A typical subject data file
        Setting up the model, the data, sending it, analyzing it.
        Evaluating the results
11:15 AM - Hands-on session - setting up big IT2B Modelling Cyclosporine -  
        Setting up the model, the data, the instructions, sending it, analyzing it, evaluating
        the results

12:30 PM LUNCH

1:30 PM - Demo Big NPEM: Modelling Cyclosporine - Dr. Hoem        
        Setting up the model, the data, the instructions, sending it, analyzing it, evaluating
        the results 
2:00 PM - Hands-on session - Big NPEM: Modelling Cyclosporine
        Setting up the model, the data, the instructions, sending it, analyzing it, evaluating
        the results

3:00 PM BREAK

3:15 PM – Optimal Experimental Design: Optimal times for getting serum levels and other responses – Dr. Jelliffe
3:45 PM - Multiple Model dosage software demo: the reason for making nonparametric models. 
          - Dr. Jelliffe 
4:15 PM – Interactive Multiple Model (IMM) Sequential Bayesian Posteriors: Detecting Unsuspected changes in Parameter Distributions during the period of Data Analysis – Dr. Jelliffe
4:45 PM - Group Discussion and Certificate Presentation